Milrod Barbara L, Leon Andrew C, Barber Jacques P, Markowitz John C, Graf Elizabeth
Department of Psychiatry, Weill Medical College of Cornell University, New York, NY 10021, USA.
J Clin Psychiatry. 2007 Jun;68(6):885-91. doi: 10.4088/jcp.v68n0610.
The American Psychiatric Association (APA) practice guideline for panic disorder recommends psychodynamic psychotherapy for panic disorder patients with comorbid personality disorders. No data underlie this recommendation. This exploratory study assessed the moderating effect of personality disorder on psychodynamic and non-psychodynamic psychotherapy outcome.
Forty-nine subjects with primary DSM-IV panic disorder were randomly assigned to 12 weeks of twice-weekly Panic-Focused Psychodynamic Psychotherapy or Applied Relaxation Training. The primary outcome measure was the Panic Disorder Severity Scale; the moderating effect of Axis II psychopathology on the Sheehan Disability Scale was also tested. The trial was conducted between February 2000 and January 2005.
Twenty-four subjects (49%) met DSM-IV criteria for a Structured Clinical Interview for DSM-IV Axis II Disorders-diagnosed personality disorder, of whom 19 (79%) had a cluster C diagnosis. Presence of a cluster C diagnosis moderated treatment outcome. Such subjects experienced greater improvements in Panic-Focused Psychodynamic Psychotherapy than subjects without cluster C comorbidity.
Despite its small sample size, this exploratory analysis provides initial preliminary evidence corroborating the APA practice guideline recommendation. Future panic disorder clinical trials should explore Axis II moderator effects.
ClinicalTrials.gov identifier NCT00128388.
美国精神病学协会(APA)关于惊恐障碍的实践指南建议,对合并人格障碍的惊恐障碍患者采用心理动力心理治疗。但该建议并无数据支持。这项探索性研究评估了人格障碍对心理动力心理治疗和非心理动力心理治疗效果的调节作用。
49名患有原发性DSM-IV惊恐障碍的受试者被随机分配,接受为期12周、每周两次的针对惊恐的心理动力心理治疗或应用放松训练。主要结局指标是惊恐障碍严重程度量表;还测试了轴II精神病理学对希恩残疾量表的调节作用。该试验于2000年2月至2005年1月进行。
24名受试者(49%)符合DSM-IV轴II障碍结构化临床访谈诊断的人格障碍标准,其中19名(79%)为C类诊断。C类诊断的存在调节了治疗效果。与无C类共病的受试者相比,这类受试者在针对惊恐的心理动力心理治疗中经历了更大的改善。
尽管样本量较小,但这项探索性分析提供了初步证据,证实了APA实践指南的建议。未来的惊恐障碍临床试验应探索轴II调节效应。
ClinicalTrials.gov标识符NCT00128388。